结合多种抗凝策略的仿贻贝 PDAM/赖氨酸/肝素复合涂层的构建,ACS Applied Materials & Interfaces

当前位置： X-MOL 学术 › ACS Appl. Mater. Interfaces › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

结合多种抗凝策略的仿贻贝 PDAM/赖氨酸/肝素复合涂层的构建
ACS Applied Materials & Interfaces ( IF 8.3 ) Pub Date : 2023-05-30 , DOI: 10.1021/acsami.3c05077
Yongqi Zhang _{1,

2} , Jia Man _{1,

2} , Jianing Liu ₃ , Jianyong Li _{1,

2} , Xinzhong Song _{1,

2} , Jiali Wang ₃ , Jianfeng Li _{1,

2} , Yuguo Chen ₃

Affiliation

体外循环的血栓形成会导致严重的并发症，严重影响患者的生命安全。然而，肝素等静脉抗凝剂可能会引起出血、超敏反应和其他不良反应。在这项研究中，在常用的医用聚（氯乙烯）（PVC）管上构建了由聚多巴胺（PDAM）、赖氨酸和改性肝素组成的受贻贝启发的复合涂层，通过结合抗凝剂的固定化和构建来减少血栓形成生物惰性表面策略。首先，通过共沉积反应在多巴胺和赖氨酸的混合溶液中构建富含胺基的PDAM/赖氨酸涂层。然后，将修饰的肝素共价固定在PDAM/赖氨酸涂层上，得到复合涂层。最后，测试了肝素的移植密度和稳定性以及复合涂层的抗凝血性能。结果表明，复合涂层能显着抑制血小板的粘附和活化，显着延长活化的部分凝血活酶时间（APTT）25 s以上。该复合涂层还具有优良的血液相容性，溶血率小于0.5%。特别是抗凝涂层在体外血液循环试验中表现良好。在这项工作中构建的复合涂层在医疗器械的抗凝治疗中显示出巨大的潜力。结果表明，复合涂层能显着抑制血小板的粘附和活化，显着延长活化的部分凝血活酶时间（APTT）25 s以上。该复合涂层还具有优良的血液相容性，溶血率小于0.5%。特别是抗凝涂层在体外血液循环试验中表现良好。在这项工作中构建的复合涂层在医疗器械的抗凝治疗中显示出巨大的潜力。结果表明，复合涂层能显着抑制血小板的粘附和活化，显着延长活化的部分凝血活酶时间（APTT）25 s以上。该复合涂层还具有优良的血液相容性，溶血率小于0.5%。特别是抗凝涂层在体外血液循环试验中表现良好。在这项工作中构建的复合涂层在医疗器械的抗凝治疗中显示出巨大的潜力。

"点击查看英文标题和摘要"

Construction of the Mussel-Inspired PDAM/Lysine/Heparin Composite Coating Combining Multiple Anticoagulant Strategies

The thrombosis of the extracorporeal circuits leads to serious complications, which affect the life safety of the patients significantly. However, intravenous anticoagulants such as heparin may induce bleeding, hypersensitivity, and other adverse reactions. In this study, the mussel-inspired composite coating consisting of polydopamine (PDAM), lysine, and modified heparin was constructed on the commonly used medical poly(vinyl chloride) (PVC) tubes to reduce thrombosis by combining the immobilization of anticoagulants and the construction of bioinert surface strategies. First, the PDAM/lysine coating rich in amine groups was constructed in a mixed solution of dopamine and lysine through the co-deposition reaction. Then, the modified heparin was covalently immobilized on the PDAM/lysine coating to obtain composite coating. Finally, the graft density and stability of heparin and anticoagulant properties of the composite coating were tested. The results showed that the composite coating could inhibit the adhesion and activation of platelets significantly and prolong the activated partial thromboplastin time (APTT) remarkably for over 25 s. The composite coating also had excellent hemocompatibility, and the hemolysis ratio was less than 0.5%. Particularly, the anticoagulant coating performed well in the in vitro blood circulation test. The composite coating constructed in this work show great potential in the anticoagulant treatment for medical devices.

更新日期：2023-05-30

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南